OMEGA THERAPEUTICS, INC.

(OMGA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Certain Stock Options of Omega Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 26-JAN-2022.

01/26/2022 EDT

Certain Stock Options of Omega Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 26-JAN-2022. These Stock Options will be under lockup for 181 days starting from 29-JUL-2021 to 26-JAN-2022. Details: The company's directors and executive officers and holders of substantially all of company's outstanding capital stock, have agreed that, without the prior written consent of Goldman Sachs & Co. LLC, Jefferies LLC and Piper Sandler & Co., Company and they will not, subject to certain exceptions, during the period ending 180 days after the date of this prospectus, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of company's common stock or any securities convertible into or exercisable or exchangeable for common stock; or enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of our common stock, whether any transaction described above is to be settled by delivery of company's common stock or such other securities, in cash or otherwise.


© S&P Capital IQ 2022
All news about OMEGA THERAPEUTICS, INC.
05/24Goldman Sachs Adjusts Price Target for Omega Therapeutics to $4 From $7, Retains Neutra..
MT
05/23Piper Sandler Lowers Omega Therapeutics' Price Target to $7 From $30, Maintains Overwei..
MT
05/06Wedbush Adjusts Price Target on Omega Therapeutics to $24 From $30, Keeps Outperform Ra..
MT
05/04OMEGA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition a..
AQ
05/04Omega Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31,..
CI
04/29Omega Therapeutics Hires Aldeyra Therapeutics Chief Financial Officer Joshua Reed for S..
MT
04/29Omega Therapeutics Announces Appointment of Joshua Reed as Chief Financial Officer
PR
04/29Omega Therapeutics Announces Appoints Joshua Reed as Chief Financial Officer, Effective..
CI
04/29Omega Therapeutics, Inc. Announces Executive Changes
CI
04/28OMEGA THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
More news
Analyst Recommendations on OMEGA THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 0,36 M - -
Net income 2022 -104 M - -
Net cash 2022 63,7 M - -
P/E ratio 2022 -1,16x
Yield 2022 -
Capitalization 121 M 121 M -
EV / Sales 2022 161x
EV / Sales 2023 -
Nbr of Employees 80
Free-Float 96,3%
Chart OMEGA THERAPEUTICS, INC.
Duration : Period :
Omega Therapeutics, Inc. Technical Analysis Chart | OMGA | US68217N1054 | MarketScreener
Technical analysis trends OMEGA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 2,53 $
Average target price 16,25 $
Spread / Average Target 542%
EPS Revisions
Managers and Directors
Mahesh Karande President, Chief Executive Officer & Director
Joshua Reed Chief Financial & Accounting Officer
Noubar B. Afeyan Chairman
Thomas McCauley Chief Scientific Officer
Yan Moore Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
OMEGA THERAPEUTICS, INC.-77.67%121
MODERNA, INC.-41.86%58 733
LONZA GROUP AG-24.79%44 437
IQVIA HOLDINGS INC.-21.85%41 736
SEAGEN INC.-8.54%26 026
ICON PUBLIC LIMITED COMPANY-26.61%18 478